A61K 40/4206
Fibroblast growth factor receptors [fgfr]
Official title: {Fibroblast growth factor receptors [FGFR]}
A61K40/4206 (Fibroblast growth factor receptors [fgfr]) appears on 3 US grants and 6 published applications in this corpus.
Search patents in A61K- Granted patents
- 3
- Published applications
- 6
- Assignees
- 8
- Inventors
- 18
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 1 |
| 2018 | 0 | 1 |
| 2019 | 2 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Single domain antibodies and their use in cancer therapies7 Apr 2026US 12,594,302 B2Centre National De La Recherche Scientifique
- Delivery methods and compositions for nuclease-mediated genome engineering22 Oct 2019US 10,450,585 B2Sangamo Therapeutics, Inc.
- Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors16 Apr 2019US 10,259,858 B2Xyphos Biosciences Inc.
- Single Domain Antibodies and Their Use in Cancer Therapies9 Jul 2026US 2026/0191907 A1Centre National De La Recherche Scientifique
- Anti-fgfr3 antibody and use thereof28 Mar 2024US 2024/0101684 A1
- Single Domain Antibodies and Their Use in Cancer Therapies28 Sep 2023US 2023/0302050 A1Centre National De La Recherche Scientifique
- Delivery methods and compositions for nuclease-mediated genome engineering2 Apr 2020US 2020/0102577 A1Sangamo Therapeutics, Inc.
- Insertable variable fragments of antibodies and modified alpha1-alpha2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors17 May 2018US 2018/0134765 A1AvidBiotics Corp.
Most cited
By later US patents
- Delivery methods and compositions for nuclease-mediated genome engineering6US 10,450,585 B2Sangamo Therapeutics, Inc. · 2019
- Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors3US 10,259,858 B2Xyphos Biosciences Inc. · 2019